Therapeutic Vaccines Development for Leukemia
Alfa Cytology is leading the way in the advancement of sophisticated immunotherapies for the treatment of leukemia. With a steadfast commitment to innovation, we tirelessly explore groundbreaking treatments for leukemia. Our comprehensive support to researchers and pharmaceutical companies In the realm of therapeutic interventions for leukemia is aimed at developing an effective vaccine against leukemia and finding a solution.
Introduction to Vaccination Therapy for Leukemia
Despite the notable advancements achieved in chemotherapy and targeted therapy, the challenge of relapse remains a significant concern. Consequently, there is increasing interest in leukemia vaccine development, which aims to elicit cellular immune responses against residual leukemia stem cells. This innovative approach shows considerable potential, particularly for older individuals afflicted with relapsed acute myeloid leukemia, offering them a novel treatment alternative.
Fig. 1. Main mechanisms for vaccine-based immunotherapy production and function in acute myeloid leukemia (AML). (Barbullushi, K. et al., 2022)
Types of Therapeutic Vaccines
Peptide-based Vaccines
The different subtypes of leukemia require a personalized approach. Key factors to prioritize in the development of peptide-based vaccines include
- appropriate leukemia antigen
- selection of immunogenic adjuvants
Nucleic acid-based Vaccines
Nucleic acid vaccines (NAVs) have recently been introduced for cancer treatment. DNA and mRNA vaccines transmit genetic information encoding a tumor antigen (TA) to the host, which subsequently mounts an immune response against TA-expressing cancer cells.
Cell-based Vaccines
Cell-based vaccine development includes genetically modifying leukemia cells to express co-stimulatory and immunostimulatory cytokines ligands to solve the problem of low immunogenicity of leukemia cell vaccines during vaccine development.
After immune checkpoint inhibitors, chimeric antigen receptor T-cell (CAR-T) therapy, and antibody-drug conjugates (ADCs), therapeutic cancer vaccines are expected to be the next standard-of-care innovation in cancer care. Alfa Cytology provides comprehensive therapeutic vaccine development services, including but not limited to the following.
Alfa Cytology offers comprehensive support in developing vaccine strategies for peptide vaccine antigens and facilitates the vaccine development process for leukemia. Leukemia antigens are the basis of peptide vaccines.
- Wilms tumor 1 (WT1)
- Proteinase 3 (PR3)
- Mucin 1 protein (MUC1)
- Receptor for hyaluronic acid-mediated motility
Using advanced biogenetic engineering technologies, Alfa Cytology engineers leukemia cells at the genetic level, opening the way for cell-based leukemia vaccine development, including but not limited to the following.
- CD80-expressing leukemia cells
- Dendritic cells
- CD40-expressing leukemia cells
- GM-CSF secreting leukemia cells
Alfa Cytology provides extensive solutions for DNA vaccine development, facilitating the fulfillment of diverse vaccine needs and expediting the progression of your leukemia DNA vaccine development project toward clinical trials.
Advantages of Our Services
- Scientific professional team
- Advanced technology platform
- Customized services
- Efficient communication and cooperation
- Years of experience in cancer vaccine development
Alfa Cytology has focused on cancer vaccines for many years, particularly developing leukemia vaccines. We are committed to providing the highest quality service and support to developers of leukemia vaccine treatments. Contact our team and let’s accelerate the research and development of a vaccine for leukemia together.
Reference
- Barbullushi, K.; et al. Vaccination therapy for acute myeloid leukemia: where do we stand? Cancers. 2022, 14(12): 2994.